Philip W. Kantoff

90.6k total citations · 19 hit papers
619 papers, 48.2k citations indexed

About

Philip W. Kantoff is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Philip W. Kantoff has authored 619 papers receiving a total of 48.2k indexed citations (citations by other indexed papers that have themselves been cited), including 445 papers in Pulmonary and Respiratory Medicine, 175 papers in Molecular Biology and 146 papers in Oncology. Recurrent topics in Philip W. Kantoff's work include Prostate Cancer Treatment and Research (406 papers), Prostate Cancer Diagnosis and Treatment (173 papers) and Cancer, Lipids, and Metabolism (93 papers). Philip W. Kantoff is often cited by papers focused on Prostate Cancer Treatment and Research (406 papers), Prostate Cancer Diagnosis and Treatment (173 papers) and Cancer, Lipids, and Metabolism (93 papers). Philip W. Kantoff collaborates with scholars based in United States, Canada and United Kingdom. Philip W. Kantoff's co-authors include Omid C. Farokhzad, Jinjun Shi, Richard Wooster, Eric J. Small, William Oh, Celestia S. Higano, Anthony V. D’Amico, David F. Penson, Susan Halabi and Robert Dreicer and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Philip W. Kantoff

599 papers receiving 47.1k citations

Hit Papers

Cancer nanomedicine: prog... 1997 2026 2006 2016 2016 2010 2002 2008 2006 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Cancer nanomedicine: progress, challenges and opportunities
    2016 4.6k citations Philip W. Kantoff, Omid C. Farokhzad et al. profile →
  2. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
    2010 4.1k citations Philip W. Kantoff, Celestia S. Higano et al. profile →
  3. Gene expression correlates of clinical prostate cancer behavior
    2002 1.8k citations Jerome P. Richie, Massimo Loda et al. profile →
  4. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
    2008 1.7k citations Susan Halabi, Celestia S. Higano et al. Journal of Clinical Oncology profile →
  5. Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
    2006 1.4k citations Omid C. Farokhzad, Jianjun Cheng et al. Proceedings of the National Academy of Sciences profile →
  6. Early Detection of Prostate Cancer: AUA Guideline
    2013 872 citations Stephen J. Freedland, Philip W. Kantoff et al. profile →
  7. Quantum Dot−Aptamer Conjugates for Synchronous Cancer Imaging, Therapy, and Sensing of Drug Delivery Based on Bi-Fluorescence Resonance Energy Transfer
    2007 751 citations Sangyong Jon, Philip W. Kantoff et al. profile →
  8. Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
    2010 727 citations Philip W. Kantoff et al. Journal of Clinical Oncology profile →
  9. Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study
    1999 694 citations Philip W. Kantoff, Susan Halabi et al. Journal of Clinical Oncology profile →
  10. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
    1997 676 citations Edward L. Giovannucci, Meir J. Stampfer et al. Proceedings of the National Academy of Sciences profile →
  11. 6-Month Androgen Suppression Plus Radiation Therapy vs Radiation Therapy Alone for Patients With Clinically Localized Prostate Cancer
    2004 599 citations Philip W. Kantoff et al. profile →
  12. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
    2014 551 citations Paul L. Nguyen, Anthony V. D’Amico et al. European Urology profile →
  13. Pamidronate to Prevent Bone Loss during Androgen-Deprivation Therapy for Prostate Cancer
    2001 542 citations Matthew R. Smith, Francis J. McGovern et al. profile →
  14. Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
    2003 541 citations Susan Halabi, Eric J. Small et al. Journal of Clinical Oncology profile →
  15. Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer
    2002 520 citations Joel S. Finkelstein, Francis J. McGovern et al. profile →
  16. Treatment of Advanced Prostate Cancer
    2019 508 citations Philip W. Kantoff et al. profile →
  17. Androgen Suppression and Radiation vs Radiation Alone for Prostate Cancer
    2008 491 citations Philip W. Kantoff et al. profile →
  18. Update on Systemic Prostate Cancer Therapies: Management of Metastatic Castration-resistant Prostate Cancer in the Era of Precision Oncology
    2018 325 citations Karim Fizazi, Stephen J. Freedland et al. European Urology profile →
  19. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
    2017 251 citations Wanling Xie, Meredith M. Regan et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philip W. Kantoff United States 101 22.8k 16.9k 12.3k 8.3k 5.8k 619 48.2k
Ian F. Tannock Canada 95 16.7k 0.7× 9.6k 0.6× 16.6k 1.4× 8.1k 1.0× 2.2k 0.4× 426 44.1k
Andreas von Deimling Germany 105 10.4k 0.5× 22.7k 1.3× 9.1k 0.7× 13.1k 1.6× 3.6k 0.6× 652 59.5k
Kenneth J. Pienta United States 116 17.5k 0.8× 21.8k 1.3× 18.0k 1.5× 12.1k 1.5× 7.2k 1.2× 675 49.8k
Michael Weller Germany 126 17.1k 0.8× 33.2k 2.0× 16.5k 1.3× 17.0k 2.0× 12.2k 2.1× 1.2k 89.1k
Lindsey A. Torre United States 13 23.0k 1.0× 35.1k 2.1× 32.3k 2.6× 23.7k 2.9× 6.1k 1.1× 14 93.9k
David N. Louis United States 99 17.5k 0.8× 27.9k 1.6× 15.3k 1.2× 17.0k 2.0× 3.8k 0.7× 322 75.2k
Patrick Y. Wen United States 102 11.6k 0.5× 12.3k 0.7× 9.9k 0.8× 8.0k 1.0× 3.0k 0.5× 781 43.2k
Peter L. Choyke United States 119 32.5k 1.4× 13.7k 0.8× 7.7k 0.6× 5.8k 0.7× 3.0k 0.5× 1.1k 64.4k
Jill S. Barnholtz‐Sloan United States 69 9.3k 0.4× 11.6k 0.7× 7.1k 0.6× 7.6k 0.9× 2.9k 0.5× 435 41.2k
Roger Stupp Switzerland 85 13.9k 0.6× 15.7k 0.9× 9.5k 0.8× 10.7k 1.3× 3.8k 0.7× 376 49.8k

Countries citing papers authored by Philip W. Kantoff

Since Specialization
Citations

This map shows the geographic impact of Philip W. Kantoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip W. Kantoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip W. Kantoff more than expected).

Fields of papers citing papers by Philip W. Kantoff

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip W. Kantoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip W. Kantoff. The network helps show where Philip W. Kantoff may publish in the future.

Co-authorship network of co-authors of Philip W. Kantoff

This figure shows the co-authorship network connecting the top 25 collaborators of Philip W. Kantoff. A scholar is included among the top collaborators of Philip W. Kantoff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip W. Kantoff. Philip W. Kantoff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ravi, Praful, Wanling Xie, Marc Buyse, et al.. (2024). Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. European Urology. 87(2). 217–224. 2 indexed citations
2.
Mostaghel, Elahe A., Brett T. Marck, Orpheus Kolokythas, et al.. (2021). Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer. Clinical Cancer Research. 27(21). 6001–6011. 17 indexed citations
3.
Pan, Wenting, Zhouwei Zhang, Fangfang Qu, et al.. (2021). Abiraterone Acetate Induces CREB1 Phosphorylation and Enhances the Function of the CBP-p300 Complex, Leading to Resistance in Prostate Cancer Cells. Clinical Cancer Research. 27(7). 2087–2099. 24 indexed citations
4.
Allott, Emma H., Ericka M. Ebot, Konrad H. Stopsack, et al.. (2019). Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. Clinical Cancer Research. 26(5). 1086–1093. 43 indexed citations
5.
Mostaghel, Elahe A., Eunpi Cho, Ailin Zhang, et al.. (2017). Association of Tissue Abiraterone Levels and SLCO Genotype with Intraprostatic Steroids and Pathologic Response in Men with High-Risk Localized Prostate Cancer. Clinical Cancer Research. 23(16). 4592–4601. 31 indexed citations
6.
Choudhury, Atish D., Anna C. Schinzel, Maura B. Cotter, et al.. (2016). Castration Resistance in Prostate Cancer Is Mediated by the Kinase NEK6. Cancer Research. 77(3). 753–765. 30 indexed citations
7.
Chan, June M., Amy K. Darke, Kathryn L. Penney, et al.. (2016). Selenium- or Vitamin E–Related Gene Variants, Interaction with Supplementation, and Risk of High-Grade Prostate Cancer in SELECT. Cancer Epidemiology Biomarkers & Prevention. 25(7). 1050–1058. 47 indexed citations
8.
Qu, Fangfang, Wanling Xie, Mari Nakabayashi, et al.. (2016). Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer. Clinical Cancer Research. 23(3). 726–734. 73 indexed citations
9.
Botta, Ginevra, Shuai Gao, Tiantian Li, et al.. (2015). PLZF, a Tumor Suppressor Genetically Lost in Metastatic Castration-Resistant Prostate Cancer, Is a Mediator of Resistance to Androgen Deprivation Therapy. Cancer Research. 75(10). 1944–1948. 46 indexed citations
10.
Wang, Xiaodong, Ying Huang, Amanda L. Christie, et al.. (2015). Cabozantinib Inhibits Abiraterone's Upregulation of IGFIR Phosphorylation and Enhances Its Anti–Prostate Cancer Activity. Clinical Cancer Research. 21(24). 5578–5587. 16 indexed citations
11.
McNeel, Douglas G., Thomas A. Gardner, Celestia S. Higano, et al.. (2014). A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. Cancer Immunology Research. 2(10). 988–999. 44 indexed citations
12.
Schoenfeld, Jonathan D., Danielle N. Margalit, Julie L. Kasperzyk, et al.. (2013). A Single Nucleotide Polymorphism in Inflammatory Gene RNASEL Predicts Outcome after Radiation Therapy for Localized Prostate Cancer. Clinical Cancer Research. 19(6). 1612–1619. 14 indexed citations
13.
Pomerantz, Mark M., Lillian Werner, Wanling Xie, et al.. (2011). Association of Prostate Cancer Risk Loci with Disease Aggressiveness and Prostate Cancer–Specific Mortality. Cancer Prevention Research. 4(5). 719–728. 32 indexed citations
14.
Penney, Kathryn L., Saumyadipta Pyne, Fredrick R. Schumacher, et al.. (2010). Genome-wide Association Study of Prostate Cancer Mortality. Cancer Epidemiology Biomarkers & Prevention. 19(11). 2869–2876. 38 indexed citations
15.
Penney, Kathryn L., Claudia A. Salinas, Mark M. Pomerantz, et al.. (2009). Evaluation of 8q24 and 17q Risk Loci and Prostate Cancer Mortality. Clinical Cancer Research. 15(9). 3223–3230. 42 indexed citations
16.
Ross, Robert W., William Oh, Wanling Xie, et al.. (2008). Inherited Variation in the Androgen Pathway Is Associated With the Efficacy of Androgen-Deprivation Therapy in Men With Prostate Cancer. Journal of Clinical Oncology. 26(6). 842–847. 90 indexed citations
17.
Michaelson, M. Dror, Donald S. Kaufman, Hang Lee, et al.. (2007). Randomized Controlled Trial of Annual Zoledronic Acid to Prevent Gonadotropin-Releasing Hormone Agonist–Induced Bone Loss in Men With Prostate Cancer. Journal of Clinical Oncology. 25(9). 1038–1042. 235 indexed citations
18.
Farokhzad, Omid C., Jianjun Cheng, Benjamin A. Teply, et al.. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of the National Academy of Sciences. 103(16). 6315–6320. 1353 indexed citations breakdown →
19.
Signoretti, Sabina, Maira M. Pires, James W. Horner, et al.. (2005). p63 regulates commitment to the prostate cell lineage. Proceedings of the National Academy of Sciences. 102(32). 11355–11360. 121 indexed citations
20.
Schilsky, Richard L., Lynn Dressler, Donna Bucci, et al.. (2002). Cooperative group tissue banks as research resources: the cancer and leukemia group B tissue repositories.. PubMed. 8(5). 943–8. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ian F. Tannock Breakdown of academic impact, for papers by Andreas von Deimling Breakdown of academic impact, for papers by Kenneth J. Pienta Breakdown of academic impact, for papers by Michael Weller Breakdown of academic impact, for papers by Lindsey A. Torre Breakdown of academic impact, for papers by David N. Louis Breakdown of academic impact, for papers by Patrick Y. Wen Breakdown of academic impact, for papers by Peter L. Choyke Breakdown of academic impact, for papers by Jill S. Barnholtz‐Sloan Breakdown of academic impact, for papers by Roger Stupp
Rankless by CCL
2026